Morphimmune, led by ex-Seagen CEO Clay Siegall, merges with Immunome in $125M deal to advance oncology therapies

Biotech startup Morphimmune, led by former Seagen CEO Clay Siegall, is merging with public company Immunome in a $125 million deal backed by private investors, creating a new company focused on oncology therapies headquartered in Seattle. Siegall will lead the merged entity as CEO, president, and chairman, building on his track record in drug development and targeting innovative cancer treatment methods.

No comments yet.